Find Academic Supervisors

M meritxell Cabré Boqué is a PhD student and active researcher at the IQS School of Engineering , affiliated with the Department of Analytical and Applied Chemistry. Her work spans Nanoparticle Analysis and Food Fraud Detection , utilizing advanced analytical techniques. University: IQS Role: Researcher and PhD Student Research Focus: Meritxell specializes in Nanoparticle characterization via ICP-MS for nanotheranostics applications, addressing challenges in Pharmaceutical Science and Environmental Toxicology . She also contributes to Food Science by profiling phenolic and mineral compounds in herbal beverages using mass spectrometry, with implications for food fraud prevention. Recent Publications: Her work includes studies on gold nanoparticle interactions in nanotheranostics (2024) and advanced mass spectrometry applications for beverage analysis (2023). Labs & Teams: Meritxell collaborates on an ongoing project titled Single Particle-ICP-MS i Single Cell-ICP-MS: Tècniques avançades per a la caracterització de la interacció entre nanopartícules i cèl·lules cap a la nanoteragnosis (2022–2026), working alongside Prof. Jordi Abellà Iglesias and other researchers.

• Nanoparticle Analysis
• Food Fraud Detection
• Analytical Chemistry
• +3 more

Professor Anh Phan is a faculty member at Newcastle University specializing in sustainable chemical engineering. His research focuses on process intensification, biomass conversion, and waste valorization for renewable energy and materials, evidenced by over 50 publications spanning 2007-2025 including two 2025 papers. His primary research areas include: Reaction Engineering: Advancing oscillatory baffled reactors for biodiesel production, glycerolysis, and reactive crystallization Waste-to-Value Conversion: Catalytic pyrolysis of plastic waste, biomass gasification for hydrogen, and aerogel synthesis from agricultural residues Advanced Materials: Developing carbon nanostructures for supercapacitors and nanotheranostic drug delivery systems Analysis of his 15 most recent publications reveals strong trends in computational optimization of thermochemical processes, circular economy applications for plastic/agricultural waste, and interdisciplinary expansion into sustainable agriculture and biomedical engineering. His work consistently bridges fundamental reaction engineering with practical sustainability challenges through innovative reactor design and waste valorization strategies.

• Reaction Engineering
• Process Intensification
• Biomass Conversion
• +4 more

Erik Sveberg Dietrichs is a Professor at the Department of Experimental Medicine, University of Oslo, leading the Translational Cardiovascular Pharmacology research group. He specializes in clinical pharmacology and is actively involved in translational research bridging cardiovascular disease, pharmacogenomics, and hypothermia therapy. Affiliated with the Institute for Experimental Medical Research Member of the Academy for Young Researchers Active on the pharmacology board of the Norwegian Society for Pharmacology and Toxicology His research spans pharmacology, psychiatry, and critical care, focusing on drug effects in cardiovascular and neurological contexts. Recent work explores hypothermia's impact on cellular signaling, antiarrhythmic drug properties, and pharmacokinetics in Parkinson's patients. Key trends in his 2022–2025 publications include nanotheranostics for aging-related diseases, dopamine agonist monitoring in Parkinson's, and cardiovascular drug responses during hypothermia. His work often integrates in vitro models and translational approaches. Scientific contributions recognized through: Membership in the Academy for Young Researchers Editorial board participation with the Norwegian Society for Pharmacology and Toxicology Contact: esdietrichs@medisin.uio.no , e.s.dietrichs@medisin.uio.no

• Pharmacology
• Cardiac research
• Cardiovascular disease
• +4 more

Aditi Mulgaonkar, Ph.D., is an Instructor in the Department of Radiology at UT Southwestern Medical Center, affiliated with its Radiology Research Division. She previously served as a senior research associate in the Cyclotron and Radiochemistry Program, supporting Dr. Xiankai Sun's work on theranostic macromolecules. Her research focuses on radiotherapeutic nanoseeds, cancer theranostics, and antibody-based tumor detection using PET imaging, resulting in 14 peer-reviewed publications. Dr. Mulgaonkar holds a pharmacy degree from the University of Mumbai, a Ph.D. in pharmaceutical sciences from Virginia Commonwealth University, and postdoctoral training at the FDA and UT Southwestern. Her research interests emphasize molecular imaging advancements, particularly in bacterial infections and cancer diagnostics. She is a member of the Society of Nuclear Medicine and Molecular Imaging and contributes to editorial roles in journals like EC Pharmaceutical Science and International Journal of Nanomedicine. Her work spans drug transport studies, nanocrystal synthesis, and imaging techniques for CAR T-cell therapy. Ongoing projects include developing novel HIF2a PET tracers and refining immunoPET imaging for PD-L1 expression in renal cell carcinoma models. Her contributions bridge clinical translation and precision medicine, with a focus on nanotheranostics and radiolabeling strategies.

• Molecular Imaging
• Nanomedicine
• Cancer Detection
• +4 more

MARIA DOLORES PITARCH GARRIDO is a Professor in the Department of Geography at the Faculty of Geography and History, University of Valencia. She is affiliated with the Inter-university Institute for Local Development (IIDL) and actively contributes to two research groups: INNODES (Innovation and Local Development) and RIUMED (Mediterranean Hydrology). Her academic focus lies in Human Geography, with extensive research on urban and territorial dynamics. Her research interests center on Human Geography , particularly in the areas of urban planning, tourism geography, social innovation, territorial resilience, and climate change vulnerability . She also investigates demographic trends, gender issues in STEM, and accessibility to public services. Her work emphasizes socio-spatial equity and sustainable development, especially in the Valencian Community and broader Spanish context. The most recent publications reflect a strong focus on tourism impacts, urban accessibility, and climate adaptation. Themes include short-term rental stress, post-pandemic tourism shifts, and climate-resilient infrastructure. Her interdisciplinary approach combines spatial analysis, social theory, and policy evaluation to address contemporary urban challenges. She has contributed to EU initiatives such as the EQUALS–EU project, promoting gender equality in STEM. Her advisory role includes supervising academic theses and guiding research on territorial development. She has been involved in projects assessing sustainability in tourist destinations using SDG frameworks and evaluating social innovation in cultural heritage. Her research is conducted within collaborative frameworks, including the INNODES and RIUMED groups, and through the IIDL. These teams focus on local development, hydrological systems in the Mediterranean, and innovative strategies for territorial resilience. Her work integrates geographic technologies to measure spatial equity and improve urban planning.

• Human Geography
• Urban Planning
• Tourism Geography
• +7 more

Ariadna Verdaguer Ferrer is a Researcher at the Department of Analytical and Applied Chemistry within IQS School of Engineering . Her work focuses on advanced analytical techniques for environmental and biomedical applications. Education: PhD in Chemistry (2012, URL) Chemical Engineering (2006, IQS) Bachelor of Chemistry (2003, URL) Research Interests: Characterization of water, contaminated soils, and industrial waste; development of electrochemical sensors for fusion reactors; analysis of pharmaceutical and environmental samples; and non-invasive cancer diagnostics through extracellular vesicle analysis using ICP-MS. Key Projects: Leading the AVEx project for early cancer detection and contributing to EQBA (Electrochemistry and Bioanalysis Group) and SEMOlMETFUS sensor development initiatives. Collaborations: Works with institutions like AGAUR and Agencia Estatal de Investigación, focusing on proton conductors, dielectric spectroscopy, and gold nanoparticle applications.

• Analytical Chemistry
• Environmental Analysis
• Electrochemistry
• +5 more

Amy Fu is an active researcher specializing in nanomedicine and biophotonics with significant contributions to developing nanotechnology-based solutions for disease diagnosis and treatment. Her work focuses on creating innovative nanoparticle systems for targeted drug delivery, bioimaging applications, and point-of-care diagnostics, particularly for neurological conditions and cancer. With an ORCID profile (0000-0001-8871-358X) showing 20 research outputs between 2012-2023, she maintains an active research trajectory in the biomedical nanotechnology field. Research Focus: Her primary research interests include biophotonics for early-stage disease diagnosis, upconversion nanocrystals for targeted drug delivery systems, super-resolution bioimaging to study nanoparticle-cell interactions, and advanced nano-bio hybrids for cancer and neurodegenerative disease therapy. She has developed specialized DNA biosensors and transduction mechanisms for genosensing applications. Her fingerprint analysis reveals strong expertise in nanoparticle research (100%), DNA chemistry (87%), and upconversion nanomaterials (33%). Publication Trends: Analysis of her recent publications (2019-2023) shows a consistent focus on overcoming the blood-brain barrier using novel nanoparticle systems, with particular emphasis on upconversion nanomaterials and poly(amidoamine) dendrimers. Her work bridges nanotechnology, neuroscience, and cancer therapeutics, demonstrating innovation in nanocarrier design, cellular uptake mechanisms, and therapeutic applications for glioma and neurodegenerative conditions. The publications show strong interdisciplinary collaboration across materials science, pharmacology, and biomedical engineering. Research Projects: OOA_Brain Foundation: In vitro testing of thrombotic nanodisks for vascular targeting of AVMs (2019) - Served as Co-Investigator alongside Principal Investigator Zhao, Z. and collaborators Stoodley, M., Shi, B., and McRobb, L. Collaboration Network: Her research shows significant external collaboration across multiple territories, with strong connections in nanoparticle research, DNA chemistry, and surface science. She maintains active research partnerships with colleagues including Shi, B., Stoodley, M., Wang, G., Lu, Y., and Chung, R. in the development of nanomedicine applications.

• Biophotonics
• Nanomedicine
• Drug Delivery Systems
• +7 more

Shasha He is a Professor in the Department of Chemistry at Xiamen University's College of Chemistry and Chemical Engineering, holding this position since 2022. Her research bridges polymer chemistry and biomedical applications with a focus on cancer immunotherapy diagnostics and therapeutics. Education: Bachelor of Chemistry, Liaoning University (2008-2012) PhD, State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences (2012-2017) Postdoctoral Researcher, School of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University, Singapore (2018-2022) Her principal research explores Biomedical Polymers and Nanomedicine for Immunotherapy , specializing in molecular probe design for disease detection. Current work centers on activatable near-infrared probes, semiconducting polymer nanoregulators, and charge-reversal nano-modulators that enable precise tumor microenvironment targeting. Her publications reveal strong emphasis on translating polymer nanotechnology into clinical cancer applications, particularly for real-time immunotherapy monitoring through urine biomarkers and non-invasive imaging. Recent publications (2020-2023) demonstrate significant contributions to Angewandte Chemie , Nature Biomedical Engineering , and Journal of the American Chemical Society , with recurring themes in photodynamic immunotherapy, T-cell tracking, and CRISPR/Cas9 gene editing regulation. Her work consistently integrates molecular imaging with therapeutic functions in a theranostic framework.

• Biomedical Polymers
• Nanomedicine
• Immunotherapy
• +2 more

Mady Elbahri is an Associate Professor at Aalto University, Finland, leading the Nanochemistry and Nanoengineering research groups. His work bridges nanotechnology, materials science, and nanomedicine with applications in defense, energy, and healthcare. Elbahri's research centers on plasmonic and polarizonic metasurfaces for thermal camouflage (2025 Advanced Materials ), nanocellulose-derived energy storage systems (2024 Advanced Functional Materials ), and antiviral nanotherapeutics for SARS-CoV-2. A unifying thread is his pioneering use of Leidenfrost phenomena for green nanochemistry synthesis, enabling sustainable nanofabrication without toxic reagents. His interdisciplinary approach integrates photonics, electrochemistry, and biomaterials engineering to solve real-world problems. Analysis of his 15 most recent publications reveals dominant trends: (1) optical metasurfaces for infrared stealth and thermal management, (2) biomass-derived carbon aerogels for adaptive supercapacitors, and (3) nanofibrous platforms for viral treatment and wound healing. His work consistently appears in high-impact journals including Advanced Materials and Nature Communications , with his 2013 Leidenfrost nanochemistry paper establishing foundational methods for eco-friendly nanomaterial production. Elbahri directs the Nanochemistry and Nanoengineering research groups at Aalto University, fostering collaborations across Europe and the Middle East. His team specializes in plasmonic absorbers, nanofibrous membranes, and Leidenfrost-based synthesis techniques with applications spanning military camouflage, renewable energy storage, and biomedical devices.

• Plasmonics
• Nanotechnology
• Materials Science
• +5 more

Kit S. Lam is a Distinguished Professor and Chairman Emeritus in the Department of Biochemistry and Molecular Medicine at the University of California Davis School of Medicine. He also serves as Professor of Hematology & Oncology and holds the Sue Jane Leung Presidential Chair in Cancer Research. Dr. Lam is a board-certified medical oncologist and laboratory investigator who pioneered the field of combinatorial chemistry. B.A. in Microbiology (1975) - University of Texas at Austin Ph.D. in Oncology (1980) - McArdle Laboratory for Cancer Research, University of Wisconsin M.D. (1984) - Stanford University School of Medicine Internal Medicine residency and Medical Oncology Fellowship - University of Arizona Dr. Lam's research spans combinatorial chemistry, chemical biology, drug development, molecular imaging, and nanotheranostics. He is renowned for inventing the 'one-bead-one-compound' (OBOC) combinatorial library method published in Nature in 1991, which has been cited over 2,500 times. His laboratory focuses on developing revolutionary methods for disease treatment at the nano-scale, including cancer targeting ligands for imaging and therapy, nanotheranostic agents, and exosome diagnostics. Recent work includes developing tumor-targeting nanoparticles, membrane-active peptides, and novel platforms for cancer immunotherapy. Analysis of Dr. Lam's recent publications (2021-2023) reveals a strong focus on nanomedicine applications in cancer therapy, particularly in targeted drug delivery, immunotherapy enhancement, and diagnostic imaging. His work consistently integrates combinatorial chemistry approaches with nanotechnology to address challenges in cancer treatment, including drug resistance, tumor microenvironment modulation, and precision targeting. Key themes include bispecific nano-immunoengagers, tumor-associated macrophage imaging, and metabolic pathways in cancer radioresistance. Dr. Lam has received numerous prestigious awards throughout his career: Sue Jane Leung Presidential Chair in Cancer Research (2018) American Peptide Society's Vincent du Vigneaud Award (2013) Harold Albin Johnson Endowed Chair in Biomedical Research (2010-2021) Award of the Society of Combinatorial Sciences (2007) UC Davis Dean's Award for Excellence in Mentoring (2007) Leukemia Scholar of the Leukemia and Lymphoma Society As co-director of the Cancer Therapeutic Program at the UC Davis NCI-designated Comprehensive Cancer Center, Dr. Lam has secured significant grant funding for his research. He served on the NCI Board of Scientific Counsellor from 2016-2022 and serves on the External Advisory Boards of multiple cancer centers. His laboratory has developed numerous patented technologies including the OBOC combinatorial library method, with over 37 issued US patents to his name. The Lam Lab is a multidisciplinary research team comprising chemists, biologists, engineers, and clinicians working collaboratively on nanomedicine and combinatorial chemistry projects. The lab maintains strong collaborations with the UC Davis Veterinary School of Medicine for translational research in canine and feline patients. Their state-of-the-art facilities include capabilities for combinatorial library synthesis, nanoparticle formulation, in vitro and in vivo cancer models, and advanced imaging techniques.

• Combinatorial chemistry
• Chemical biology
• Drug development
• +8 more

Richard Benninger, PhD, serves as Assistant Professor at the University of Colorado Anschutz Medical Campus School of Medicine with joint appointments in Bioengineering and Pediatrics. He directs the Advanced Light Microscopy core facility and leads a multidisciplinary research program focused on diabetes mechanisms. Education: PhD, Imperial College of Science, Technology and Medicine (2006) Research Focus: The Benninger lab applies engineering principles to study pancreatic islets of Langerhans, investigating systems biophysics in diabetes, gap junction plasticity , cell heterogeneity , and advanced imaging techniques . Their work bridges optical microscopy , ultrasound imaging , and biophysical modeling to develop diabetes diagnostics and therapeutics targeting hormone release mechanisms. Publication Trends: Analysis of 15 recent publications reveals consistent focus on islet multicellular dynamics (73% of articles), gap junction regulation (60%), and imaging technology development (47%). Temporal trends show increasing emphasis on human islet studies (2017-2020) and translational applications for type 1 diabetes diagnostics. Scientific Awards: No awards were documented in the provided materials. Academic Service: Benninger actively contributes to diabetes research through the American Diabetes Association and Biophysical Society memberships. The text contains no information regarding graduate student mentorship or grant funding. Research Infrastructure: The Benninger lab operates as a collaborative engineering-medicine unit centered around the Advanced Light Microscopy core. Their technical capabilities integrate two-photon microscopy , calcium imaging , and computational modeling to analyze islet function across molecular, cellular, and tissue scales in both mouse and human models.

• Diabetes Research
• Biophysics
• Bioengineering
• +4 more

Twan Lammers is a full Professor of Medicine at the Institute for Experimental Molecular Imaging (ExMI) within RWTH Aachen University Clinic. He leads the Nanomedicine and Theranostics research group focused on developing image-guided drug delivery systems for cancer and fibrotic diseases. Research Focus: His work centers on nanomedicine tumor targeting , combining drug delivery with molecular imaging to monitor tumor growth, angiogenesis, inflammation, and metastasis. Key areas include engineering polymeric microbubbles for ultrasound-mediated drug delivery, optimizing nanoparticle biodistribution using EPR and ATR mechanisms, and developing clinical translation frameworks for nanotherapeutics. His group pioneered transferrin receptor-targeted microbubbles for blood-brain barrier sonopermeation and desmoplastic tumor priming strategies using corticosteroid liposomes. Awards & Recognition: ERC Starting and Consolidator Grants Controlled Release Society Young Investigator Award (2015) Clarivate Highly Cited Researcher (since 2019) Over 250 publications with significant clinical impact Leadership: Serves as handling editor for Journal of Controlled Release and Molecular Imaging and Biology , and chairs special issues on stimuli-responsive nanotheranostics. His research bridges preclinical innovation with clinical applications through collaborations with pharmaceutical partners and clinical trial networks.

• Nanomedicine
• Theranostics
• Drug Delivery Systems
• +5 more

Dr. Robert R. Flavell, MD, PhD, is an Assistant Professor in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco (UCSF). He completed his MD-PhD at Weill Cornell Medical College and Rockefeller University, followed by residency and fellowship at UCSF. MD, PhD: Tri-Institutional Program (Cornell, Rockefeller, Memorial Sloan-Kettering) Residency: UCSF Radiology with NIH T32 fellowship Board Certification: Nuclear Medicine His Molecular Imaging Lab develops novel PET and hyperpolarized MRI techniques for cancer diagnostics and therapy monitoring, with a focus on prostate cancer. Key projects include: Acidic interstitial pH imaging via [18F]FDG amines (Flavell et al., Bioconjugate Chem., 2016) Quantitative pH measurement using hyperpolarized 13C bicarbonate (Flavell et al., Chem. Comm., 2015) Metal microenvironment imaging and immune activation metabolic signatures Research trends from his publications (2014-2023) show consistent innovation in: CD46-targeted alpha particle therapy (225Ac/212Pb) PSMA-targeted nanotheranostics Bacterial infection imaging via D-amino acid tracers PET/MRI hybrid imaging for metabolic and perfusion analysis Hyperpolarized 13C probes for real-time metabolic monitoring Chemoenzymatic synthesis of radiotracers Scientific honors include: Prostate Cancer Foundation Young Investigator Award (2017-2020) Society of Abdominal Radiology Stern Award (2017-2019) DoD Prostate Cancer Training Grant (2016) RSNA Certificates of Merit (2014, 2015) Dr. Flavell's work bridges radiology , biochemistry , and oncology , with emphasis on clinical translation of imaging agents. His lab collaborates with hyperpolarized imaging experts, radiochemists, and oncologists for multimodal cancer characterization.

• Molecular Imaging
• Oncologic Imaging
• Radiochemistry
• +3 more

Dr. Liyu Chen is a Postdoctoral Research Fellow at the Queensland Brain Institute (QBI), University of Queensland. His research focuses on advancing drug delivery systems for neurodegenerative diseases like Alzheimer's and ALS, with a particular emphasis on overcoming the blood-brain barrier using low-intensity ultrasound, nanoparticles, and targeted therapies. Dr. Chen holds a PhD from the Australian Institute for Bioengineering and Nanotechnology (2016), where he investigated physiological responses to polymeric materials in nanomedicine. His research interests include nanomedicine, biomedical engineering, and the development of novel therapeutic strategies for neurological disorders. He has collaborated extensively on studies involving claudin-5 binders, lipid nanoparticles, and ultrasound-mediated drug delivery, with applications in motor neuron diseases and Alzheimer's therapy. Dr. Chen's work bridges engineering and medicine, aiming to optimize drug delivery systems for enhanced efficacy and reduced toxicity. His contributions span preclinical models, in vitro studies, and translational research toward clinical applications.

• Drug Delivery
• Neuroscience
• Nanomedicine
• +4 more

Holden H Wu is a Professor in the Department of Radiological Sciences at the University of California Los Angeles (UCLA) School of Medicine. His research focuses on advanced medical imaging techniques, particularly in quantitative MRI, artificial intelligence applications, and image-guided interventions. He leads the UCLA MRRL Wu Lab and has established himself as a leading researcher in free-breathing MRI techniques for body composition analysis and disease quantification. Dr. Wu's research interests span nanotheranostics, quantitative imaging, MRI technology development, artificial intelligence applications in medical imaging, and image-guided interventions. His work particularly emphasizes developing motion-robust techniques for abdominal and pediatric imaging, with applications in liver fat quantification, body composition analysis, and prostate cancer imaging. He has pioneered several free-breathing MRI techniques that have eliminated the need for breath-holding in patients, significantly improving clinical applicability, especially for pediatric populations and patients with limited breath-holding capacity. His recent publications demonstrate a strong focus on integrating deep learning with physics-based modeling to improve quantitative MRI techniques. Major trends in his research include the development of self-gated radial MRI techniques, motion-compensated imaging methods, and AI-powered analysis tools for medical imaging data. His work bridges engineering innovation with clinical applications, particularly in liver disease, metabolic disorders, and oncology. New Technologies for Real-Time MRI-Guided Robotic-Assisted Abdominal Interventions (NIH R01EB031934, 2022-2026) - Principal Investigator Quantitative MRI and Deep Learning Technologies for Classification of NAFLD (NIH U01EB031894, 2022-2027) - Principal Investigator Quantifying Body Composition and Liver Disease in Children using Free-Breathing MRI and MRE (NIH R01DK124417, 2020-2024) - Principal Investigator Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification (NIH R01CA248506, 2020-2025) - Co-Principal Investigator Dr. Wu has mentored numerous students and researchers through his active laboratory, focusing on training the next generation of biomedical imaging scientists. His research group, the UCLA MRRL Wu Lab, develops innovative imaging technologies with direct clinical translation potential. Current projects include developing real-time MRI-guided robotic interventions, advanced quantitative techniques for liver fat and fibrosis assessment, and AI-powered prostate cancer detection methods.

• Nanotheranostics
• Quantitative Imaging
• MRI
• +2 more